WO2013026021A3 - Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease - Google Patents

Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease Download PDF

Info

Publication number
WO2013026021A3
WO2013026021A3 PCT/US2012/051426 US2012051426W WO2013026021A3 WO 2013026021 A3 WO2013026021 A3 WO 2013026021A3 US 2012051426 W US2012051426 W US 2012051426W WO 2013026021 A3 WO2013026021 A3 WO 2013026021A3
Authority
WO
WIPO (PCT)
Prior art keywords
trka
alzheimer
progression
disease
target
Prior art date
Application number
PCT/US2012/051426
Other languages
French (fr)
Other versions
WO2013026021A2 (en
Inventor
Varghese John
Qiang Zhang
Dale E. Bredesen
Original Assignee
Buck Institute For Research On Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute For Research On Aging filed Critical Buck Institute For Research On Aging
Publication of WO2013026021A2 publication Critical patent/WO2013026021A2/en
Publication of WO2013026021A3 publication Critical patent/WO2013026021A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/005—Biological teaching, e.g. a link between protein and disease, new virus causing pandemic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In various embodiments method are provided for inhibiting (partially or fully) the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) in a mammal. The methods typically involve administering or causing to be administered to the mammal a TrkA kinase inhibitor in an amount sufficient to reduce C-terminal cleavage of APP and production of a C31 peptide and/or APPneo. In certain embodiments the inhibitor comprises ADDN-1351 or a derivative thereof.
PCT/US2012/051426 2011-08-18 2012-08-17 Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease WO2013026021A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525076P 2011-08-18 2011-08-18
US61/525,076 2011-08-18

Publications (2)

Publication Number Publication Date
WO2013026021A2 WO2013026021A2 (en) 2013-02-21
WO2013026021A3 true WO2013026021A3 (en) 2013-05-10

Family

ID=47715717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/051426 WO2013026021A2 (en) 2011-08-18 2012-08-17 Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2013026021A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134042A2 (en) 2015-02-18 2016-08-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
US10800760B2 (en) * 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
AR114110A1 (en) 2018-02-28 2020-07-22 Lilly Co Eli ANTI-TRKA ANTIBODY
WO2022130175A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
CA3205020A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
WO2022184130A1 (en) * 2021-03-03 2022-09-09 成都先导药物开发股份有限公司 Nuak inhibitor and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114510A1 (en) * 2000-11-03 2003-06-19 Ingram Vernon M. Treatments for neurotoxicity in alzheimer's disease
US20050222254A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Sulfonamide compounds for the treatment of neurodegenerative disorders
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114510A1 (en) * 2000-11-03 2003-06-19 Ingram Vernon M. Treatments for neurotoxicity in alzheimer's disease
US20050222254A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Sulfonamide compounds for the treatment of neurodegenerative disorders
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BREDESEN: "'Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence.'", MOLECULAR NEURODEGENERATION, vol. 4, no. 27, 26 June 2009 (2009-06-26), pages 1 - 10 *
MATRONE ET AL.: "APP is Phosphorylated by TrkA and Regulates NGF/TrkA Signaling.", THE JOUMAL OF NEUROSCIENCE, vol. 31, no. 33, 17 August 2011 (2011-08-17), pages 11756 - 11761 *

Also Published As

Publication number Publication date
WO2013026021A2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
WO2013019901A3 (en) Tropinol esters and related compounds to promote normal processing of app
WO2013026021A3 (en) Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
AU2012214029A8 (en) Rorgammat inhibitors
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
WO2013060867A3 (en) Production of heterodimeric proteins
WO2013049726A3 (en) Processes for making compounds useful as inhibitors of atr kinase
WO2010108074A3 (en) Inhibitors of pi3 kinase
CA2818187C (en) Bromodomain inhibitors and uses thereof
MX2013005356A (en) Use of fluopyram for controlling nematodes in crops and for increasing yield.
HUE057571T2 (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
AU2013270326B2 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
IN2012DN01641A (en)
WO2013055684A8 (en) Rasagiline citramide
WO2012010978A3 (en) A method of treating alzheimer's disease
UA112764C2 (en) OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC CRYSTALLIC bile acids with a predetermined particle size
CA2834735C (en) Use of nalbuphine for treating dyskinesia
CA2837895C (en) Methods of treating or preventing neurological diseases
WO2010034006A3 (en) The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2.
WO2007076318A3 (en) Camphor-derived cxcr3 antagonists
EA201190256A1 (en) A METHOD FOR REDUCING THE LEVEL OF UBIVITILATED PROTEINS
WO2009076602A8 (en) 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
WO2009011901A3 (en) Methods for promoting wakefulness
WO2014015137A3 (en) Compositions and methods for treating dysproliferative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823518

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12823518

Country of ref document: EP

Kind code of ref document: A2